(Q33935145)

30 July 2017

1 reference

title

Clinical approach to inhaled nitric oxide therapy in the newborn with hypoxemia (English)

1 reference

30 July 2017

1 reference

J P Kinsella

1

1 reference

PubMed ID

10839866

30 July 2017

S H Abman

series ordinal

2

1 reference

PubMed ID

10839866

30 July 2017

language of work or name

English

0 references

publication date

1 June 2000

1 reference

The Journal of Pediatrics

30 July 2017

1 reference

30 July 2017

136

1 reference

30 July 2017

6

1 reference

30 July 2017

717-726

1 reference

Inhaled nitric oxide in persistent pulmonary hypertension of the newborn

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Low-dose inhalation nitric oxide in persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Randomized, multicenter trial of inhaled nitric oxide and high-frequency oscillatory ventilation in severe, persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide and persistent pulmonary hypertension of the newborn. The Inhaled Nitric Oxide Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Improved oxygenation in a randomized trial of inhaled nitric oxide for persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide for the early treatment of persistent pulmonary hypertension of the term newborn: a randomized, double-masked, placebo-controlled, dose-response, multicenter study. The I-NO/PPHN Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Low-Dose Nitric Oxide Therapy for Persistent Pulmonary Hypertension of the Newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Persistent pulmonary hypertension of the newborn infant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Neonatal pulmonary hypertension: pathophysiology, classification, and etiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Refractory hypoxemia associated with neonatal pulmonary disease: The use and limitations of tolazoline

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

The independent effects of hyperventilation, tolazoline, and dopamine on infants with persistent pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Clinical responses to prolonged treatment of persistent pulmonary hypertension of the newborn with low doses of inhaled nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Acute effects of inhaled nitric oxide in children with severe hypoxemic respiratory failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide for the adult respiratory distress syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Alveolar neutrophil functions and cytokine levels in patients with the adult respiratory distress syndrome during nitric oxide inhalation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Nitric Oxide Inhibition of Lipid Peroxidation: Kinetics of Reaction with Lipid Peroxyl Radicals and Comparison with α-Tocopherol†

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Molecular interactions between nitric oxide and lung surfactant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide reverses pulmonary vasoconstriction in the hypoxic and acidotic newborn lamb.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide in infants referred for extracorporeal membrane oxygenation: dose response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Safety of withdrawing inhaled nitric oxide therapy in persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Dipyridamole attenuates rebound pulmonary hypertension after inhaled nitric oxide withdrawal in postoperative congenital heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

In vivo evidence for a myogenic response in the fetal pulmonary circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

High-frequency ventilation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Efficacy of inhalational nitric oxide therapy in the clinical management of persistent pulmonary hypertension of the newborn

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Evidence of surfactant deficiency in persistence of the fetal circulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Improved pulmonary outcome after exogenous surfactant therapy for respiratory failure in term infants requiring extracorporeal membrane oxygenation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure. Survanta in Term Infants Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Dipyridamole augmentation of response to nitric oxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide and hypoxic respiratory failure in infants with congenital diaphragmatic hernia. The Neonatal Inhaled Nitric Oxide Study Group (NINOS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

Inhaled nitric oxide in premature neonates with severe hypoxaemic respiratory failure: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2800%2910660-2

10.1016/S0022-3476(00)10660-2

7 January 2021

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10839866